Cargando…

Immune Checkpoint Inhibitors and Neurotoxicity

Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhiyi, Zhang, Chunlin, Zhou, Lian, Dong, Pan, Shi, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719293/ https://www.ncbi.nlm.nih.gov/pubmed/33380303 http://dx.doi.org/10.2174/1570159X19666201230151224

Ejemplares similares

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
por: Farina, Antonio, et al.
Publicado: (2023)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
por: Schmitt, C., et al.
Publicado: (2023)

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
por: Vilariño, Noelia, et al.
Publicado: (2020)

Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity
por: Möhn, Nora, et al.
Publicado: (2023)

Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series
por: Marco, Carla, et al.
Publicado: (2022)

Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
por: Cordes, Lisa M., et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Are volatile anesthetics neuroprotective or neurotoxic?
por: Zuo, Zhiyi
Publicado: (2012)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab
por: Gao, Rongmao, et al.
Publicado: (2023)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
por: Duan, Lian, et al.
Publicado: (2020)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells
por: Liu, Mingyue, et al.
Publicado: (2023)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review
por: Li, Honglin, et al.
Publicado: (2023)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
por: Zhao, Xinrui, et al.
Publicado: (2020)

Immune checkpoint inhibitors in cancer patients with COVID-19
por: Pan, Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cdmnlml906o7dv8c5p8eevo709